Pancreatin enteric-coated tablets 250 mg 60 pcs.

Composition

Active ingredient: pancreatin;

1 tablet contains 250 mg of pancreatin, which corresponds to an activity of at least 1000 amylolytic U Ph. Eur., 1200 lipolytic U Ph. Eur., 80 proteolytic U Ph. Eur.;

Excipients: lactose, monohydrate; povidone; calcium stearate; acrylic pink 93O34055 [mixture of substances: methacrylate copolymer (type C), talc, titanium dioxide (E 171), triethyl citrate, carmine (E 120), colloidal anhydrous silica, sodium bicarbonate, sodium lauryl sulfate, ponceau 4R (E 124), indigo carmine (E 132)].

Release form

The film-coated tablets are enteric-coated.

Pharmacodynamics. Enzyme preparation from the pancreas of cattle and pigs. The pancreatic enzymes included in the preparation: lipase, amylase, trypsin, chymotrypsin facilitate the process of digestion of proteins, carbohydrates and fats of food, contributing to a more complete absorption of nutrients in the small intestine.

Pharmacokinetics. Due to the acid-resistant coating, the enzymes are inactivated by the action of hydrochloric acid in the stomach. The dissolution of the shell and the release of enzymes begins in the duodenum. The enzymes are poorly absorbed in the digestive tract, acting in the intestinal lumen.

• dyspepsia;
• simultaneous consumption of difficult to digest vegetable, fatty and unusual foods;
• flatulence associated with the above disorders;
• acceleration of the passage of food in the intestines of a functional nature.

Individual hypersensitivity to pancreatin or other components of the drug. acute pancreatitis, chronic pancreatitis in the acute stage, intestinal obstruction.

Adults and children over 6 years of age should take 1-2 tablets orally during or immediately after meals, without chewing, with plenty of liquid.

Depending on the type of food consumed or the severity of indigestion, take 2-4 tablets during meals for enzyme replacement therapy.

The dose of the drug and the duration of treatment are determined by the nature of the disease and are set individually by the doctor.

Children. The drug can be used in children from 6 years of age.

Intestinal obstruction – if symptoms suggestive of this condition are present, the possibility of intestinal strictures should be considered. It is recommended to monitor any unusual symptoms, especially when taking more than 10,000 lipase units/kg/day.

To avoid the formation of uric acid stones, the uric acid content in the urine should be controlled.

The drug contains active enzymes that can damage the oral mucosa, so the tablets should be swallowed whole, without chewing.

With prolonged use, iron preparations should be prescribed simultaneously.

When taking the drug before meals, it should be washed down with alkaline liquids (for example, Borjomi mineral water or 0.5-1% sodium bicarbonate solution).

The drug contains lactose, therefore, if the patient has been diagnosed with intolerance to some sugars, you should consult a doctor before taking this drug.

The dye Ponceau 4R (E124) in the preparation may cause allergic reactions.

Use during pregnancy or breastfeeding. Pancreatin can be used during pregnancy or breastfeeding only as prescribed by a doctor in cases where the expected benefit to the mother outweighs the potential risk to the fetus or child.

The ability to influence the reaction rate when driving vehicles or working with other mechanisms. Does not affect.

On the part of the digestive system: diarrhea, feeling of discomfort in the epigastric region of the stomach, nausea, vomiting, flatulence, change in the nature of stools, constipation, intestinal obstruction.

On the part of the immune system: hypersensitivity reactions are possible (including rash, itching, sneezing, lacrimation, bronchospasm, dyspnea, urticaria, anaphylactic reactions, angioedema).

Cardiovascular system: tachycardia.

General disorders: feeling hot, general weakness.

Symptoms: hyperuricemia, hyperuricosuria; in children – constipation.

When using the drug in high doses, perianal skin irritation may occur in children.

Treatment: drug withdrawal, adequate hydration, symptomatic therapy.

With simultaneous use of pancreatin with antithrombotic agents, vitamin D antagonists and acetylsalicylic acid, the effect of these drugs is reduced. The effectiveness of non-selective monoamine reuptake inhibitors is also reduced when used together with pancreatin.

When used simultaneously with M-cholinoblockers, the anticholinergic effect is enhanced.

When using the drug, there may be a decrease in the absorption of iron and folic acid, and a decrease in the severity of the hypoglycemic effect of acarbose.

Simultaneous use of antacids containing calcium carbonate and/or magnesium hydroxide, with tannin, alcohol-containing agents may lead to a decrease in the effectiveness of pancreatin.

In the original packaging at a temperature not exceeding 25 ° C. Store out of the reach of children.